about
Novel association strategy with copy number variation for identifying new risk Loci of human diseasesHuman genetics and genomics a decade after the release of the draft sequence of the human genomeBreast cancer in the personal genomics eraThe Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancerAnticancer agent shikonin is an incompetent inducer of cancer drug resistanceTransporting antitumor drug tamoxifen and its metabolites, 4-hydroxytamoxifen and endoxifen by chitosan nanoparticlesPredictive and prognostic molecular markers for cancer medicineFormulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.The Impact of CYP2D6 Genotyping on Tamoxifen TreatmentCYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic.Impact of the 1000 genomes project on the next wave of pharmacogenomic discoveryTailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.The application of gene co-expression network reconstruction based on CNVs and gene expression microarray data in breast cancer.A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivativesThe Effects of Tamoxifen in Combination with Tranilast on CXCL12-CXCR4 Axis and Invasion in Breast Cancer Cell Lines.Personalized medicine: a personal viewThe impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerUse of CYP2D6 genotyping in practice: tamoxifen dose adjustment.Effects of CYP induction by rifampicin on tamoxifen exposure.HNF4α--role in drug metabolism and potential drug target?Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq dataManipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival.Antifungal, anti-inflammatory and cytotoxicity activities of three varieties of labisia pumila benth: from microwave obtained extracts.Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifenPersonalized medicine and cancer.Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.Copy number variants in pharmacogenetic genes.Comparison of cytotoxicity and genotoxicity of 4-hydroxytamoxifen in combination with Tualang honey in MCF-7 and MCF-10A cells.Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.Novel genetic markers of breast cancer survival identified by a genome-wide association study.
P2860
Q21136178-90D10583-035F-4606-95CE-6B5C823D177BQ21245451-385C69AC-9542-4694-A5CF-B0844631CA49Q24602679-634592B7-25B6-4060-BA16-10E203EA6D49Q26782449-D4F72754-8900-46F7-B6BD-9870884B3F59Q26825584-1E50A58A-8888-4EAB-A634-0CD9513DF830Q26859144-2230E33D-EB50-4D55-BB6C-DB3145A930CFQ27001260-DEEC16A7-DD8A-4145-AC4D-C50BCDBBC121Q28484828-4723903F-A0CF-4103-81F4-DD603322A151Q28488379-94DE7FFC-EE0C-40D9-95E9-A51CD7FB56D3Q28743108-E565AD98-CF60-4220-B257-E99201585E63Q30385768-243FF549-99AA-4345-AA58-18F82272FB04Q33664433-EA56FA85-3426-4B59-B1A1-5DCF72091CF4Q33704974-6F23A7D5-1E14-4C11-BB8C-9BD6783CDFA6Q33708200-E815E05E-BE9E-40D0-900E-AC9A7E3E1E8DQ33781027-75692514-2504-4FFC-A842-034D78785E1AQ33911433-4DCF372D-0668-408C-9525-6B141392A5BEQ34125047-2302BA17-D9F2-4E2D-9A2E-B6DE93017F43Q34146185-FB16AFB7-B5E9-411A-B263-BD49F8BCCD6BQ34171954-F55701D9-1F85-4159-A566-1344F8D10F67Q34253646-A494AFB3-80CA-4ABA-BF65-83CB7B7C6E57Q34269380-64DCEC33-4FA0-4020-836B-3F8C19F5F9AFQ34278391-654A266D-A632-4FBB-899A-AB6A64AFF096Q34311568-5856DC12-CD4E-4348-BAD0-503B9FA8DDEBQ34315833-873D5B8A-09B0-4A8C-80D4-A38816F321ADQ34356351-E19E0C41-1CF7-49B4-BAAD-A5F8DA736D52Q34417159-62F74D91-6A52-45A2-BBAE-FC6AE6CDC024Q34502648-B132DCB2-A3D8-49BE-B7EF-3FAA72673914Q34561548-537350EF-DBD8-4846-99AB-574F5CCD503DQ34571065-879653D9-F998-4F3F-A7F0-185A11C68F59Q34608577-FB25017F-3459-4FB2-A290-2557A51999C5Q34620545-DBBB9E05-3C74-4943-934C-2341C4328D69Q34657786-2BFEB211-4905-4680-B119-BB29DEF5F348Q34975631-FD273E34-1B21-4F5F-A7C9-0262BB94E109Q35124800-0FC7B95A-EE38-44FC-A539-C78397A42D91Q35172199-F3A7EAD7-B862-4F59-89AF-CA0725B44A28Q35558084-E1B36E88-2B6D-4F43-A495-0DC4F6B183DCQ35747766-7E2D9DFA-8A17-46DE-A2DE-836401E61492Q35760937-2245101F-4ED7-4DDC-8B7A-53E7F407DE5BQ35768721-0E533F9F-6B0A-4D3A-A9B8-BAE358B3BEDBQ35803492-6ED49C26-DA81-4F53-B25D-9B0513ED0EAD
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@ast
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@en
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@nl
type
label
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@ast
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@en
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@nl
prefLabel
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@ast
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@en
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@nl
P2093
P356
P1476
CYP2D6 and tamoxifen: DNA matters in breast cancer.
@en
P2093
Howard L McLeod
Janelle M Hoskins
Lisa A Carey
P2888
P304
P356
10.1038/NRC2683
P407
P577
2009-08-01T00:00:00Z
P5875
P6179
1032860958